VEGFA and inflammatory skin disease: To the best of our knowledge, we describe here the first studies to explore a potential therapeutic effect in inflammatory skin disease, demonstrating that VEGF‐A inhibition by bevacizumab exerts significant anti‐angiogenic activity in skin organ culture of psoriasis.